No evidence of increased risk for Coronavirus Disease 2019 (COVID‐19) in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area – Bergamo, Lombardy, Italy
Andrea Carugno(University of Insubria), Paolo Sena(Ospedale Papa Giovanni XXIII), Donatella Gambini(Ospedale Papa Giovanni XXIII), Francesca Raponi(Ospedale Papa Giovanni XXIII), Elisa Robustelli Test(University of Cagliari), Pamela Vezzoli(Ospedale Papa Giovanni XXIII), Marco Di Mercurio(Ospedale Papa Giovanni XXIII), Andrea G. Locatelli(University College Dublin)
Cited by 48
Related Papers
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
|Journal of Allergy and Clinical Immunology|2020|160
Italian Guidelines in diagnosis and treatment of alopecia areata
|Giornale Italiano di Dermatologia e Venereologia|2019|88
Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience
|Journal of the European Academy of Dermatology and Venereology|2011|84
A dermatologic assessment of 101 mpox (monkeypox) cases from 13 countries during the 2022 outbreak: Skin lesion morphology, clinical course, and scarring
|Journal of the American Academy of Dermatology|2023|82